(NASDAQ: OCS) Oculis Holding Ag's forecast annual revenue growth rate of 415.22% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 108.19%, and it is also forecast to beat the US market's average forecast revenue growth rate of 25.27%.
Oculis Holding Ag's revenue in 2025 is $622,222.On average, 9 Wall Street analysts forecast OCS's revenue for 2025 to be $53,184,175, with the lowest OCS revenue forecast at $43,775,235, and the highest OCS revenue forecast at $67,170,418.  On average, 9 Wall Street analysts forecast OCS's revenue for 2026 to be $581,864,445, with the lowest OCS revenue forecast at $43,775,235, and the highest OCS revenue forecast at $2,403,729,425.  
In 2027, OCS is forecast to generate $5,843,770,537 in revenue, with the lowest revenue forecast at $2,413,109,832 and the highest revenue forecast at $12,839,432,782.